iShares Nasdaq Biotechnology (IBB)

Add to Watchlists
Create an Alert
313.95 +10.57  +3.48% NASDAQ Dec 18, 4:59PM BATS Real time Currency in USD
View Full Chart
IBB Price Chart

IBB Description

iShares Nasdaq Biotechnology is a long only equity fund managed by iShares that tracks the NASDAQ Biotechnology TR USD index and has 6.646B USD assets under management. It has an expected distribution yield of 0.14%, a Forecasted PE Ratio of 30.77, and a Forecasted Price to Book Value of 7.318. The fund has a net expense ratio of 0.48%, turns over its positions 39.00% per year, and is traded on the NASDAQ.

IBB Key Info

Expense Ratio (7-31-14) 0.48%
Assets Under Management (12-17-14) 6.646B
30-Day Average Volume (12-17-14) 1.289M
Net Asset Value (12-16-14) 293.91
Discount or Premium to NAV (12-17-14) -0.02%
Turnover Ratio (3-31-14) 39.00%

IBB Asset Allocation

Type % Net % Long % Short
Cash 0.00% 0.00% 0.00%
Stock 99.90% 99.90% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.10% 0.10% 0.00%
As of Dec. 16, 2014

IBB Region Exposure

Americas 95.43%
North America 95.43%
Latin America 0.00%
Greater Europe 4.51%
United Kingdom 2.28%
Europe Developed 2.23%
Europe Emerging 0.00%
Africa/Middle East 0.00%
Greater Asia 0.06%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 0.06%
Market Classification
% Developed Markets 99.94%
% Emerging Markets 0.06%
As of Dec. 15, 2014
Region breakdown data is calculated by using the long position holdings of the portfolio.

IBB Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 100.0%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of Dec. 16, 2014

IBB Stock Market Capitalization

Giant 31.65%
Large 26.51%
Medium 22.17%
Small 12.47%
Micro 7.11%
As of Dec. 16, 2014
View More Holdings

IBB Top 10 Holdings

Name % Weight Price Chg %
Celgene Corp 8.76% 116.18 +2.98%
Amgen Inc 8.65% 168.40 +3.01%
Regeneron Pharmaceuticals Inc 7.43% 423.62 +3.07%
Biogen Idec Inc 7.17% 353.33 +6.14%
Gilead Sciences Inc 7.06% 105.56 +3.09%
Vertex Pharmaceuticals Inc 4.48% 117.72 +5.25%
Mylan Inc 4.15% 56.84 +2.87%
Alexion Pharmaceuticals Inc 3.97% 188.89 +3.74%
Illumina Inc 3.69% 187.15 +3.28%
Biomarin Pharmaceutical Inc 2.62% 91.80 +5.26%
As of Dec. 16, 2014
Get Quote for
Advertisement

IBB Basic Info

Style
Asset Class Sector Equity
Prospectus Objective Specialty - Health
Fund Owner Firm Name iShares
Benchmark Index
NASDAQ Biotechnology TR USD 100.0%
Key Dates
Inception Date 2/5/2001
Last Annual Report Date 3/31/2014
Last Prospectus Date 7/31/2014
Attributes
Exchange Traded Share Yes
Exchange Traded Note No
Enhanced Index Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan Yes
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available RRSP No

IBB Manager Info

Name Tenure
Diane Hsiung 6.92 yrs
Greg Savage 6.92 yrs
Jennifer Hsui 2.33 yrs
Matthew Goff 1.18 yrs

IBB Risk Info

Beta 0.9323
30 Day Average Volatility 22.71%

IBB Fundamentals

Dividend Yield TTM (12-18-14) 0.14%
Weighted Average PE Ratio 33.59
Weighted Average Price to Sales Ratio 8.831
Weighted Average Price to Book Ratio 7.805
Weighted Median ROE 10.53%
Weighted Median ROA 2.02%
Forecasted Dividend Yield 0.20%
Forecasted PE Ratio 30.77
Forecasted Price to Sales Ratio 8.148
Forecasted Price to Book Ratio 7.318
Number of Holdings 117.00
As of Dec. 16, 2014

IBB Growth Estimates

Forecasted 5 Yr Earnings Growth 16.21%
Forecasted Book Value Growth 10.54%
Forecasted Cash Flow Growth 10.91%
Forecasted Earnings Growth 30.68%
Forecasted Revenue Growth 11.94%
As of Dec. 16, 2014

IBB Performance

  Returns Total Returns
1M 8.69% 8.69%
3M 15.01% 15.03%
6M 26.71% 26.93%
1Y 47.12% 47.38%
3Y 213.6% 215.8%
5Y 301.0% 306.3%
As of Dec. 16, 2014

IBB Flows

1M 120.84M
3M 321.02M
6M 142.98M
YTD 547.73M
1Y 539.17M
3Y 1.682B
5Y 1.185B
As of Nov. 30, 2014
Advertisement

You've hit the 10 page limit on YCharts.

Experience the power of YCharts.
Start your Free 14-Day Trial.

Start My Free Trial No credit card required.

Already a subscriber? Sign in.

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}
Start your free 14 Day Trial.

{{root.upsell.info.button_text}} No credit card required.

Already a subscriber? Sign in.